FBIO (Fortress Biotech) Current Deferred Revenue: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FBIO Fortress Biotech Inc FBIO
44 GF Score
Price $3.29
GF Value $1.26
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Fortress Biotech Current Deferred Revenue?

Fortress Biotech FBIO +0.61% 44 Current Deferred Revenue is $0.00 Mil as of Mar. 2026. GuruFocus rates FBIO with a GF Score™ of 44/100 and a GF Value™ of $1.26 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Fortress Biotech's current deferred revenue for the quarter that ended in Mar. 2026 was $0.00 Mil.

Fortress Biotech Current Deferred Revenue Related Terms

Fortress Biotech Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Fortress Biotech's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fortress Biotech Current Deferred Revenue Chart

Fortress Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.61 0.00 0.00 0.00 0.00

Fortress Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FBIO
44GF Score
Fortress Biotech Inc FBIO
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $0.00 Mil mean?
Fortress Biotech (FBIO) has a Current Deferred Revenue of $0.00 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Fortress Biotech and its competitors.
Is Fortress Biotech's Current Deferred Revenue too high?
Fortress Biotech's current Current Deferred Revenue is $0.00 Mil. Overall, Fortress Biotech has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fortress Biotech's Current Deferred Revenue compare to PMN and VANI?
Fortress Biotech's Current Deferred Revenue of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Fortress Biotech and its competitors. Fortress Biotech's current Current Deferred Revenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fortress Biotech stock overvalued right now?
Based on GuruFocus' analysis, Fortress Biotech (FBIO) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.26, compared to a current price of $3.29 — trading 161.1% above its estimated fair value. The current Current Deferred Revenue is $0.00 Mil. Fortress Biotech's overall GF Score™ is 44/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Fortress Biotech (FBIO), the current Current Deferred Revenue is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fortress Biotech (FBIO) Overvalued in 2026?

Based on GuruFocus' analysis, Fortress Biotech stock appears to be overvalued. The current stock price of $3.29 is trading 161.1% above its estimated GF Value™ of $1.26. GuruFocus considers Fortress Biotech to be Significantly Overvalued.

Key valuation signals for FBIO:

  • Current Deferred Revenue: $0.00 Mil
  • GF Value™: $1.26 vs. price of $3.29 (161.1% above fair value)
  • GF Score™: 44/100 with 7 warning signs

No single metric tells the full story. See the FBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fortress Biotech Business Description

Address 1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
44GF Score

Get the complete analysis for FBIO

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.29
Price
$1.26
GF Value